159 related articles for article (PubMed ID: 31227476)
21. Appendix 4: Chronic lymphocytic leukaemia: eUpdate published online 27 June 2017 (www.esmo.org/Guidelines/Haematological-Malignancies).
ESMO Guidelines Committee
Ann Oncol; 2017 Jul; 28(suppl_4):iv149-iv152. PubMed ID: 28881925
[No Abstract] [Full Text] [Related]
22. Expression of functional sphingosine-1 phosphate receptor-1 is reduced by B cell receptor signaling and increased by inhibition of PI3 kinase δ but not SYK or BTK in chronic lymphocytic leukemia cells.
Till KJ; Pettitt AR; Slupsky JR
J Immunol; 2015 Mar; 194(5):2439-46. PubMed ID: 25632006
[TBL] [Abstract][Full Text] [Related]
23. EZH2 Inhibition by Tazemetostat Results in Altered Dependency on B-cell Activation Signaling in DLBCL.
Brach D; Johnston-Blackwell D; Drew A; Lingaraj T; Motwani V; Warholic NM; Feldman I; Plescia C; Smith JJ; Copeland RA; Keilhack H; Chan-Penebre E; Knutson SK; Ribich SA; Raimondi A; Thomenius MJ
Mol Cancer Ther; 2017 Nov; 16(11):2586-2597. PubMed ID: 28835384
[TBL] [Abstract][Full Text] [Related]
24. Antitumor effects of celecoxib on K562 leukemia cells are mediated by cell-cycle arrest, caspase-3 activation, and downregulation of Cox-2 expression and are synergistic with hydroxyurea or imatinib.
Zhang GS; Liu DS; Dai CW; Li RJ
Am J Hematol; 2006 Apr; 81(4):242-55. PubMed ID: 16550520
[TBL] [Abstract][Full Text] [Related]
25. B-cell receptor inhibitors in chronic lymphocytic leukemia.
Flinn IW
Clin Adv Hematol Oncol; 2011 Aug; 9(8):605-6. PubMed ID: 22236988
[No Abstract] [Full Text] [Related]
26. Unravelling the suboptimal response of TP53-mutated chronic lymphocytic leukaemia to ibrutinib.
Guarini A; Peragine N; Messina M; Marinelli M; Ilari C; Cafforio L; Raponi S; Bonina S; Mariglia P; Mauro FR; Gaidano G; Del Giudice I; Foà R
Br J Haematol; 2019 Feb; 184(3):392-396. PubMed ID: 30338509
[TBL] [Abstract][Full Text] [Related]
27. Venetoclax in CLL patients who progress after B-cell Receptor inhibitor treatment: a retrospective multi-centre Italian experience.
Innocenti I; Morelli F; Autore F; Piciocchi A; Frustaci A; Mauro FR; Schiattone L; Trentin L; Del Poeta G; Reda G; Rigolin GM; Ibatici A; Ciolli S; Coscia M; Sportoletti P; Murru R; Levato L; Gentile M; D'Arena G; Efremov DG; Tedeschi A; Scarfò L; Cuneo A; Foà R; Laurenti L
Br J Haematol; 2019 Oct; 187(1):e8-e11. PubMed ID: 31364153
[No Abstract] [Full Text] [Related]
28. Synergistic Targeting of the Regulatory and Catalytic Subunits of PI3Kδ in Mature B-cell Malignancies.
Cooney JD; Lin AP; Jiang D; Wang L; Suhasini AN; Myers J; Qiu Z; Wölfler A; Sill H; Aguiar RCT
Clin Cancer Res; 2018 Mar; 24(5):1103-1113. PubMed ID: 29246942
[No Abstract] [Full Text] [Related]
29. SWI/SNF catalytic subunits' switch drives resistance to EZH2 inhibitors in ARID1A-mutated cells.
Wu S; Fatkhutdinov N; Fukumoto T; Bitler BG; Park PH; Kossenkov AV; Trizzino M; Tang HY; Zhang L; Gardini A; Speicher DW; Zhang R
Nat Commun; 2018 Oct; 9(1):4116. PubMed ID: 30297712
[TBL] [Abstract][Full Text] [Related]
30. Emerging role of kinase-targeted strategies in chronic lymphocytic leukemia.
Wiestner A
Hematology Am Soc Hematol Educ Program; 2012; 2012():88-96. PubMed ID: 23233565
[TBL] [Abstract][Full Text] [Related]
31. EZH2 in normal hematopoiesis and hematological malignancies.
Herviou L; Cavalli G; Cartron G; Klein B; Moreaux J
Oncotarget; 2016 Jan; 7(3):2284-96. PubMed ID: 26497210
[TBL] [Abstract][Full Text] [Related]
32. Hypoxia-induced p38 MAPK activation reduces Mcl-1 expression and facilitates sensitivity towards BH3 mimetics in chronic lymphocytic leukemia.
Huelsemann MF; Patz M; Beckmann L; Brinkmann K; Otto T; Fandrey J; Becker HJ; Theurich S; von Bergwelt-Baildon M; Pallasch CP; Zahedi RP; Kashkar H; Reinhardt HC; Hallek M; Wendtner CM; Frenzel LP
Leukemia; 2015 Apr; 29(4):981-4. PubMed ID: 25376373
[No Abstract] [Full Text] [Related]
33. The Ibr-7 derivative of ibrutinib exhibits enhanced cytotoxicity against non-small cell lung cancer cells via targeting of mTORC1/S6 signaling.
Zhang B; Wang L; Zhang Q; Yan Y; Jiang H; Hu R; Zhou X; Liu X; Feng J; Lin N
Mol Oncol; 2019 Apr; 13(4):946-958. PubMed ID: 30663221
[TBL] [Abstract][Full Text] [Related]
34. Ibrutinib interferes with the cell-mediated anti-tumor activities of therapeutic CD20 antibodies: implications for combination therapy.
Da Roit F; Engelberts PJ; Taylor RP; Breij EC; Gritti G; Rambaldi A; Introna M; Parren PW; Beurskens FJ; Golay J
Haematologica; 2015 Jan; 100(1):77-86. PubMed ID: 25344523
[TBL] [Abstract][Full Text] [Related]
35. ABT-199 for chronic lymphocytic leukemia.
Seymour J
Clin Adv Hematol Oncol; 2014 Oct; 12(10):698-700. PubMed ID: 25658896
[No Abstract] [Full Text] [Related]
36. Ibrutinib: searching for a partner drug.
Kater AP; Brown JR
Lancet Oncol; 2019 Jan; 20(1):3-5. PubMed ID: 30522966
[No Abstract] [Full Text] [Related]
37. Bone marrow stroma-induced resistance of chronic lymphocytic leukemia cells to arsenic trioxide involves Mcl-1 upregulation and is overcome by inhibiting the PI3Kδ or PKCβ signaling pathways.
Amigo-Jiménez I; Bailón E; Aguilera-Montilla N; Terol MJ; García-Marco JA; García-Pardo A
Oncotarget; 2015 Dec; 6(42):44832-48. PubMed ID: 26540567
[TBL] [Abstract][Full Text] [Related]
38. Blocking EZH2 methylation transferase activity by GSK126 decreases stem cell-like myeloma cells.
Zeng D; Liu M; Pan J
Oncotarget; 2017 Jan; 8(2):3396-3411. PubMed ID: 27926488
[TBL] [Abstract][Full Text] [Related]
39. Idelalisib improves CD37 antibody BI 836826 cytotoxicity against chemo-resistant /relapse-initiating CLL cells: a rationale for combination treatment.
Betrian S; Ysebaert L; Heider KH; Delord JP; Fournié JJ; Quillet-Mary A
Blood Cancer J; 2016 Nov; 6(11):e496. PubMed ID: 27834943
[No Abstract] [Full Text] [Related]
40. Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia.
Cervantes-Gomez F; Lamothe B; Woyach JA; Wierda WG; Keating MJ; Balakrishnan K; Gandhi V
Clin Cancer Res; 2015 Aug; 21(16):3705-15. PubMed ID: 25829398
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]